Breaking AI & Tech News Analyzed

A Day of Artful ParentingThere's a special magic in introducing young children to the world of art, especially when it happens in the comfort of home. This narrative follows a parent and toddler as they navigate a day filled with creative expression, from building animal houses with colorful magnet tiles to exploring the welcoming spaces of a local gallery.Creating an Artistic Home EnvironmentThe journey begins in the child's bedroom, where walls are adorned with playful prints by artist Moira Frith and a William Nicholson piece of the Velveteen Rabbit. The ceiling features elephant and bee mobiles alongside Japanese paper animal balloons, creating an immersive artistic space that welcomes the child into a world of creativity from the moment they wake up.Morning Art AdventuresThe day commences with art-themed board books featuring Miffy, the little white rabbit, and an interactive color-mixing book. Despite the artistic focus, the toddler's attention naturally shifts to his plastic tractor, demonstrating how children naturally balance different interests. The morning continues with building a house for farm animals using colorful magnet tiles, stacking wooden blocks, and experimenting with stickers on paper.The Gallery ExperienceAfter a brief outdoor chalk-drawing interlude, the parent and child visit the William Morris Gallery, which the child affectionately calls "the gallery." This familiar space offers crayons, blank paper, building blocks, and soft toys—all set against an artistic backdrop. The gallery has become a regular Wednesday destination with the child's grandmother, representing how cultural institutions can be woven into family routines.Art Education for the Very YoungChildren naturally lack hierarchical distinctions about what constitutes art, embracing everything from professional paintings to their own scribbles. This democratic approach to creativity allows for boundless exploration and expression. The article suggests that both home-based art activities and gallery visits play complementary roles in nurturing young artistic sensibilities.Cultivating Future Art EnthusiastsAs the child grows, the parent envisions future art adventures, possibly even a trip to the Miffy Museum in Utrecht for the child's second birthday. This forward-looking perspective suggests that early artistic experiences can blossom into lifelong appreciation of creativity and culture.Resources for Young ArtistsFor parents looking to bring art into their homes, the article recommends several books:Miffy the Artist by Dick Bruna (also Miffy at the Gallery, and Miffy and the Artists)Famous Art to Colour by Susan MeredithThis Book Will Make You an Artist by Ruth Millington

The Breakthrough in Breast Cancer TreatmentA landmark international study has revealed that millions of women with breast cancer could safely skip chemotherapy thanks to a genomic test that determines who needs the treatment and who doesn't. The randomised trial specifically examined whether the test could identify patients who would not benefit from chemotherapy, allowing them to avoid the potentially debilitating treatment without compromising their outcomes.The Scientific Evidence Behind the TestThe results of the Optima trial, which will be presented at the American Society of Clinical Oncology's annual meeting, are being hailed by experts as gamechanging. The five-year cancer-free survival rate was 93.7% in the group that skipped chemotherapy, which was statistically non-inferior to the 94.9% rate in patients randomly assigned to receive chemotherapy.The Prosigna genomic test analyzes the activity of 50 specific genes in tumor tissue to determine the molecular subtype and develops a risk of recurrence score to help doctors decide if chemotherapy is necessary. This precision medicine approach allows for personalized treatment decisions based on the unique characteristics of each patient's cancer.A Patient's Journey to Avoiding ChemotherapyKaren Bonham, a speech and language therapist from Swansea in Wales, was one of 4,429 patients with breast cancer recruited to the trial from countries including the UK, Norway, Sweden, Australia, New Zealand and Thailand. Diagnosed with cancer in 2017 at the age of 55 after routine breast screening, Bonham described the news as shocking."It certainly propels you into a world of uncertainty. Life priorities realign – you simply want to survive," she said. Dreading chemotherapy, she agreed to join the Optima trial after undergoing surgery. She was only days away from starting treatment and had already cut her hair short when the results came back in September 2017.While taking a walk on a Welsh beach, Bonham received a phone call from her hospital informing her she had been allocated to the group of patients that would not be having chemotherapy. "How to describe the initial feeling? Immense relief? Like Christmas? Certainly a mixture of the two," she said.The Future of Personalized Cancer CareToday, Bonham, now 64, retired and living in Cardiff, is free of cancer, healthy and shows no signs of the disease coming back. "It is coming up to nine years since my diagnosis," she said. "I am mindful of my diagnosis, alert to potential changes in my body but do not feel defined by [it]. I walk, enjoy yoga and live well."While not every woman with breast cancer will be able to skip chemotherapy—the treatment remains necessary and important for many—the trial results suggest that genomic testing can safely identify those who can avoid it. This approach represents a significant shift toward personalized medicine in oncology, reducing unnecessary treatment and its associated side effects while maintaining excellent outcomes."I hope that the trial will bring positive patient outcomes to many," Bonham said, reflecting on the potential impact of this research on future breast cancer patients.

Scientists from University College London and partners have proved that a 50‑gene genomic test can reliably pinpoint hormone‑positive breast‑cancer patients who do not need chemotherapy, potentially sparing millions from toxic side‑effects.Optima Trial Demonstrates Genomic Test Can Identify Low‑Risk PatientsThe Optima trial enrolled 4,429 women aged 40+ across the UK, Norway, Sweden, Australia, New Zealand and Thailand. Participants were split into a standard‑care arm (chemotherapy + hormone therapy) and a test‑guided arm where treatment was decided by the genomic score.Trial Numbers Reveal Near‑Identical Survival RatesFive‑year outcomes were strikingly similar:95% of patients receiving chemotherapy remained alive and recurrence‑free.94% of patients who skipped chemotherapy (low‑score group) were also alive and recurrence‑free.The test classified patients using a score derived from the activity of 50 tumour genes, produced by Veracyte's Prosigna assay.These figures indicate that for low‑score patients, chemotherapy adds little or no survival benefit.Potential Shift in Breast Cancer Treatment GuidelinesProf Rob Stein, chief investigator, says the results “address a longstanding challenge” by moving decision‑making from clinical features to tumour biology. Health systems could see reduced drug costs, fewer hospital visits, and a dramatic drop in chemotherapy‑related toxicity.Future Adoption and Healthcare SavingsWith funding from the NIHR, Veracyte and cancer charities, the study paves the way for rapid guideline updates at bodies like ASCO and NICE. Wider implementation could translate into billions of dollars saved globally and improve quality of life for countless patients. Ongoing monitoring will confirm long‑term outcomes, but the early data suggest a new era of personalised, cost‑effective breast‑cancer care.

Early Reading Memories Virginia Evans shares her earliest reading memory, reading either 'The Velveteen Rabbit' by Margery Williams or poems from 'Where the Sidewalk Ends' by Shel Silverstein with her sister. Favorite Books Growing Up Evans loved mysteries and fantasy worlds, reading many Nancy Drew books, 'The Boxcar Children' by Gertrude Chandler Warner, and 'The Wind in the Willows'. She enjoyed books about things that can't exist, calling it escapism. The Book That Changed Her as a Teenager At 15, Evans read John Steinbeck's 'The Grapes of Wrath', which gave her a new understanding of what fiction can do and how words can portray complex living. The Writer Who Changed Her Mind Evans praises Joan Didion, saying every time she reads Didion's work, she is changed in some way, seeing the world, people, and politics differently. The Book That Made Her Want to Be a Writer In college, Evans read Jhumpa Lahiri's 'Interpreter of Maladies', which inspired her to write, making her think: 'I have to do this, I can do this, I will do this'. The Author She Came Back To Evans tried Jane Austen's 'Pride and Prejudice' too young, but when she came back to it in her late 20s, she enjoyed it tremendously. Books She Rereads Daphne du Maurier's 'Rebecca' Steinbeck's 'East of Eden' The Book She Could Never Read Again Evans devoured the Millennium series by Stieg Larsson but was too disturbed to read it again. The Book She Discovered Later in Life Evans didn't read 'Little Women' by Louisa May Alcott until her adult life, relating to the mother character and identifying with Jo's struggles as an author. Current and Comfort Reads Currently reading: 'While I Was Gone' by Sue Miller Comfort reads: 'The Uncommon Reader' by Alan Bennett, 'Beautiful Ruins' by Jess Walter, 'I Capture the Castle' by Dodie Smith

Translated Fiction Review Roundup A collection of recent translated fiction has been reviewed, showcasing the diversity and complexity of global literature. The reviews include: 'Sisters in Yellow' by Mieko Kawakami Sisters in Yellow by Mieko Kawakami, translated by Laurel Taylor and Hitomi Yoshio (Picador, £16.99) Kawakami’s latest opens with a bang, as narrator Hana learns that her old friend Kimiko has been charged with abduction. This MacGuffin takes us to their friendship in late-1990s Tokyo, when teen Hana and the older woman open a bar called Lemon: “Yellow attracts money.” But it’s a turbulent ride and soon Hana is in a world of organised crime. “The world is crazy. I feel like I’m living in a manga.” She’s not the only one, and you need an appetite for Kawakami’s style, which prefers to explore rather than explain – people come and go, buildings burn down, cancer is diagnosed, almost at random – but the relentless rush means there’s no time to get bored. At its best – as in a scene where Hana’s unreliable mother wants to borrow 2m yen for investment in lingerie that helps “your spine and organs move back to where they’re supposed to be” – this is a story both absurd and horrifying. 'All Flesh' by Ananda Devi All Flesh by Ananda Devi, translated by Jeffrey Zuckerman (Pushkin, £12.99) “Forgive me for starting this story with bodily, unpalatable origins.” You may as well – it’s all like that. In an unnamed European country, a schoolgirl “born with no urge but to consume” is getting bigger and bigger. “My gut, my ass, my thighs – they were all set on reaching the farthest corners of the world.” She blames her gluttony on the need to silence the voice of her dead twin sister, who was “absorbed into my tissues” in the womb. She hates school, where other kids mock her, as though her own self-disgust weren’t enough. After a blackly comic scene where she gets stuck in her bedroom doorframe like “an uncooperative cork”, she falls in love with the lonely carpenter who arrives to widen the door – but there are more twists to come. This powerful story is deeply physical, but driven by a compelling voice describing the torment of a girl who is “the psychical mirror of our time … immoderation made manifest”. 'The White Desert' by Luis López Carrasco The White Desert by Luis López Carrasco, translated by Rosalind Harvey (Granta, £14.99) This unpredictable book, comprising five linked stories about a Spanish couple, opens with the end of the world and gets weirder from there. A balloon debate about a post-apocalyptic scenario turns nasty when one participant pulls a knife, or thinks he does. A plane crash-lands on an island. “Can [we] go and get our luggage … Lots of people have, you know, soiled themselves.” What links the scenes is a sense of disconnection in our connected world, but the book subverts expectations: when a group of people celebrating New Year’s Eve go missing, it turns out to be a game of hide and seek. Footnotes peppered throughout suggest we’re viewing all this from the future (“Emirates was a well-known passenger airline …”), and discovering what the white desert is turns everything on its head. For readers who like to do their own joining up, and who want a playful, original take on our precarious lives, this is a thought-provoking treat. 'The Home of the Drowned' by Elin Anna Labba The Home of the Drowned by Elin Anna Labba, translated by Elizabeth Clark Wessel (Harvill, £16.99) “You could have waited, you bastards.” In 1942 Lapland, a village occupied by the semi-nomadic Sámi people is flooded by a new hydroelectric plant’s dam. One family watch as their goahti (peat-covered hut) disappears under the water. “It wasn’t the nicest goahti,” says Ánne. “No, but it was mine,” says her sister Rávdná. When Rávdná wants to build a house to replace it, the authorities refuse permission: the Sámi way of life has been rejected but alternatives are not permitted. A local newspaper half-heartedly offers to publicise their case, but “we receive a lot of angry letters if we use any foreign words”. When the government tells local people the new dam “will lift us out of poverty and injustice”, the words reek with irony. This intimate story of infuriating discrimination is, Labba says, based on real events in Sweden.

The LeadA daily pill has shown remarkable results in doubling survival time for patients with pancreatic cancer, the world's deadliest form of the disease. According to clinical trial results presented at the American Society of Clinical Oncology's annual meeting, this breakthrough treatment represents a potential revolution in how we approach a cancer that has seen limited progress for decades.The Breakthrough Drug: DaraxonrasibThe drug in question, daraxonrasib, works by targeting a protein called Kras that fuels nearly all pancreatic cancers. This mechanism represents a significant advancement in treatment strategy, as Kras has been notoriously difficult to target effectively. The drug functions as a Ras(On) multi-selective inhibitor, capable of turning off the Kras protein to stop cancer growth regardless of which variant is present.Impressive Trial ResultsIn the clinical trial involving 500 patients with advanced pancreatic cancer, the results were striking. Those who took daraxonrasib lived an average of 13.2 months, compared to just 6.6 to 6.7 months for patients who received chemotherapy. This represents a near doubling of survival time, with the added benefit of fewer side effects compared to traditional chemotherapy treatments.Industry Impact and Expert ReactionsThe findings have been hailed as a "gamechanger" and "grand slam" by experts in the field. Dr. Rachna Shroff, chief of oncology at the University of Arizona Cancer Center, described the results as "landscape-changing" and "unprecedented survival." When she first read the trial results, conducted by researchers at the Dana-Farber Cancer Institute in Boston, she wept, noting the profound impact this could have on patients after 16 years of treating pancreatic cancer.Dr. Julie Gralow, Asco's chief medical officer, echoed these sentiments, calling the study a "home run" and suggesting it was actually a "grand slam" in terms of its significance.The Ras RevolutionOver 90% of patients with the most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (mPDAC), have a mutation in the Kras gene. This discovery has long been considered the "holy grail" in cancer research, particularly for pancreatic cancer where the mutation is nearly ubiquitous and an early driver of cancer growth.Paula Hanford, chief executive of UK-based Pancreatic Cancer Action, called this one of the most significant developments in treatment she had ever seen. Similarly, Anna Jewell, director of services, research and innovation at Pancreatic Cancer UK, described the results as "exciting," noting that the drug gives patients "months more precious time with their loved ones."Future Outlook and ApplicationsThe success of daraxonrasib opens doors for similar treatments targeting Ras genes in other cancers. Experts at the conference noted that because Ras genes fuel various types of cancer, there is hope for breakthroughs in treating lung and colon cancers as well, with similar drugs already in development for these conditions.However, challenges remain in ensuring these promising treatments become widely available to patients. As Jewell pointed out, tragically half of all people with pancreatic cancer die within just three months of diagnosis, making the rapid implementation of such treatments crucial.

The Lead: Unprecedented Cancer Treatment SuccessDoctors have hailed "unprecedented" trial results that show a triple-action cancer jab can eradicate entire tumours in patients. In an international trial spanning 11 countries, the injection was offered to patients whose cancer had spread or come back and whose disease had failed to respond to other treatments.The Breakthrough: Amivantamab's Triple-Action ApproachThe jab, called amivantamab, shrank the tumours of more than a third of patients, with dramatic changes seen within weeks. In 15 of them, doctors found the drug had melted away their tumours altogether.The smart jab targets cancer in three ways. It blocks both EGFR (epidermal growth factor receptor), a protein that helps tumours grow, and MET, a pathway that cancer cells often use to escape treatment. It also helps activate the immune system to attack the tumour.The Clinical Trial Data: Impressive Response RatesIn the trial, 102 patients with head and neck cancer, the world's sixth most common cancer, were given the jab. Tumours shrank or disappeared completely in 43 patients, including 28 whose tumours shrank significantly and 15 who saw them eradicated entirely.Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working.The Impact Analysis: New Hope for Treatment-Resistant CancersKevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, London (ICR), said: "These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy. This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking."Researchers also highlighted that the trial focused on people with head and neck cancers that did not include those with human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma. That is particularly significant, they said, since head and neck cancers not caused by HPV are usually harder to treat, making progress in this group hugely important.The Patient Experience: Transforming Quality of LifeOne of the first patients to benefit was Carl Walsh, 56, who was diagnosed with tongue cancer in May 2024 and joined the OrigAMI-4 trial at the Royal Marsden in July 2025. "I was initially treated with both chemotherapy and immunotherapy, which unfortunately were not successful," he said. "At that point, I was recommended for the OrigAMI-4 trial. I'm now on my 17th cycle of treatment and I'm very pleased with the progress so far."Unlike many cancer treatments, amivantamab is given as a tiny jab under the skin rather than via an intravenous drip, making treatment quicker and more convenient for patients and much easier to deliver in outpatient clinics.The Future Outlook: Expanding Treatment ApplicationsThe results will be presented on Sunday in Chicago at the world's largest cancer conference, the annual meeting of the American Society of Clinical Oncology (Asco).Amivantamab, developed by Johnson & Johnson, is now being evaluated in about 60 clinical trials, primarily for lung cancer, but also for colorectal, brain and gastric cancers.Prof Kristian Helin, the chief executive of the ICR, said: "This study demonstrates how the development of new treatments through rigorous cancer research may lead to meaningful advances, even for patients with very limited treatment options. Achieving this level of tumour response and encouraging survival outcomes in such a challenging-to-treat group represents a significant step forward."

Russell T Davies' New DramaRussell T Davies, known for 'It's a Sin', brings a new culture wars drama to Channel 4. 'Tip Toe' explores the modern state of LGBTQ+ communities, tackling themes of identity and acceptance.Other Highlights9pm, Channel 4: 'Tip Toe', a powerful drama about culture wars in LGBTQ+ communities.9pm, BBC Two: 'The Mother of All Cons', a documentary about a charity backed by One Direction.8.15pm, BBC One: 'Death Valley', a cosy crimer investigating a suspicious death on a TV series set.9pm, BBC One: 'Dear England', a drama about Gareth Southgate and the England football team.10pm, ITV1: 'The Assembly Unseen', a series featuring autistic, neurodivergent and learning-disabled people asking questions of celebrities.Film and Sport10.30pm, BBC One: 'The Nice Guys', a 2016 caper film starring Ryan Gosling and Russell Crowe.7pm, BBC Two: Athletics: Diamond League, live from Rabat, Morocco.

The Lead: A Provocative Debut Rozie Kelly's frank and feisty debut novel, Kingfisher, has been shortlisted for this year's Women's Prize for Fiction and begins with a case of lust at first sight. The unnamed narrator, a 35-year-old writer, becomes infatuated with a famous poet 17 years his senior, setting the stage for a complex exploration of desire, power dynamics, and unconventional relationships. The Novel's Premise: An Unconventional Attraction The novel introduces us to a "beautiful" 35-year-old writer in a complicated but loving relationship with the equally beautiful but somewhat boring Michael. The object of his sudden attraction is a renowned poet running a popular course at the same university. Despite barely knowing her, he experiences an intense desire "to be inside her," expressing surprise at his own reaction: "A woman! What was the world coming to?" The narrator's infatuation is initially fueled by the poet's success, wealth, and fame, though he also admits to wanting to subjugate her, "to push her down, to render her imperious intelligence stupid with the weight of my body." Thematic Exploration: Love, Lust, and Power Kelly shrewdly explores the different forms love and lust can take, complicated by shifting power dynamics. The relationship begins when the poet and narrator meet to discuss his (nonexistent) poetry collection, leading to an unexpected night together. As their relationship develops, particularly after the poet receives a terminal cancer diagnosis, they settle into the rhythms of a loving relationship. The narrative also explores the narrator's complicated relationship with his racist and homophobic mother, Hetty, confined to a care home, and his deteriorating relationship with Michael, who eventually leaves him for a younger partner. Narrative Structure: Stylistic Uncertainties Despite a confident start and intriguing premise, Kingfisher suffers from narrative inconsistencies. Interesting characters are established then forgotten, and narrative threads are never fully developed. The novel struggles with tonal shifts, moving from "bracing language and violent desires" to "bedside solicitude and quiet domesticity." A late-stage shift into gothic fantasy further destabilizes the narrative, with the ending dangerously approaching "it was all a dream" territory. Throughout, the narrator questions the nature of their relationship: "Who's using who here, do we think?" The answer, as presented in the novel, is that both characters are using each other, as "writers on the make; everyone is potential copy." Critical Assessment: Verve Without Fire Kingfisher possesses considerable verve and energy, demonstrating Kelly's willingness to take risks and embrace absurdity. The novel "crackles and sparks," but ultimately "never quite catches fire." While the book successfully challenges conventional narratives about love and desire, particularly through its exploration of non-traditional relationships and power dynamics, it fails to maintain its initial momentum. The narrative uncertainty and inconsistent tone prevent what could have been a groundbreaking exploration of contemporary relationships from achieving its full potential.